Results 171 to 180 of about 48,606 (211)

An Extended Transcriptomic Landscape of Human Skin Mast Cells: Unveiling Lineage‐Specific Noncoding RNA Dynamics in FcεRI Activation

open access: yesAllergy, EarlyView.
FcεRI cross‐linking triggers widespread transcriptional reprogramming in human skin mast cells (> 5000 genes, > 6400 promoters, and 48 novel mast cell‐enriched lncRNAs). Breast skin and foreskin mast cells share core transcriptional programs but differ selectively in tryptase isoenzymes and IL‐8/IL‐1RA release.
Gürkan Bal   +12 more
wiley   +1 more source

Mesenchymal Stem Cells From a Klinefelter Syndrome Patient: Functional Characterization and Therapeutic Implications

open access: yesAndrology, EarlyView.
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz   +12 more
wiley   +1 more source

Umbilical Cord Blood–Derived Extracellular Vesicles Enhance Neurovascular Regeneration and Improve Erectile Function in a Mouse Model of Bilateral Cavernous Nerve Injury

open access: yesAndrology, EarlyView.
ABSTRACT Background Erectile dysfunction (ED) secondary to cavernous nerve injury (CNI), such as that occurring after radical prostatectomy, remains a significant clinical challenge, particularly among patients who do not respond to phosphodiesterase Type 5 inhibitors (PDE5i).
Minh Nhat Vo   +6 more
wiley   +1 more source

Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

open access: yesBrain Pathology, EarlyView.
Omics‐driven drug repositioning reveals pyroxamide as a neuroprotective HDAC1 inhibitor in Parkinson's disease models. Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other ...
Paz Cartas‐Cejudo   +7 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Peripheral targets for neuropathic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour   +3 more
wiley   +1 more source

Repurposed catechol‐O‐methyltransferase inhibitors tolcapone and entacapone preferentially suppress aggregation and seeding of P301 mutant tau in human neuronal models

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and purpose Pathogenic aggregation and propagation of seed‐competent TAU assemblies drive tauopathies. MAPT P301 mutations accelerate aggregation and enhance seed competence, yet pharmacological strategies selectively targeting these pathogenic species remain limited.
Ihor Kozlov   +6 more
wiley   +1 more source

Interaction with NEGR1 affects mGlu5 cell signalling and the neuroprotection induced by the positive allosteric modulator VU0409551

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The metabotropic glutamate receptor mGlu5 plays an important role in neuronal survival and synaptic plasticity. We and others have shown that mGlu5 positive allosteric modulators (PAMs) are biased agonists, triggering the activation of neuroprotective pathways and promoting neuronal survival. As mGlu5 biased pharmacology
Jennifer D. S. Guimaraes   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy